Sibylla was founded by Emiliano Biasini, Pietro Faccioli, Giovanni Spagnolli, Maria Letizia Barreca, Graziano Lolli.

Who are Sibylla's investors?

Sibylla's investors include 3B Future Health Fund, CDP Venture Capital, Seroba Life Sciences, V-Bio Ventures, Vertis SGR, VI Partners, Claris Ventures, Indaco Venture Partners.

Where is Sibylla headquartered?

Sibylla is headquartered in Trento, IT.

Sibylla

Trento, IT · 42 employees on LinkedIn · 8 known investors

Find your way into Sibylla

Paths you didn't know you had: your email and LinkedIn already hold routes to the Sibylla team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution. The company focuses on protein misfolding diseases, particularly prion diseases.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

Emiliano Biasini Co-founderEmiliano Biasini is a research scientist and biochemistry professor who leads the Dulbecco Telethon Laboratory of Prions & Amyloids at the University of Trento, where he investigates protein misfolding mechanisms and neurodegeneration. Co-founder of Sibylla Biotech, he applies expertise in biochemistry, molecular biology, and biophysics to develop drug discovery technologies for prion diseases.

Pietro Faccioli Co-founderPietro Faccioli holds a background in theoretical high-energy physics and has applied statistical and quantum mechanics to biophysics problems, including non-equilibrium biomolecular transitions and quantum dynamics in biological molecular systems. He is co-founder of Sibylla Biotech, which develops computational approaches to study protein folding pathways.

Giovanni SpagnolliCo-founder, CTO

Maria Letizia Barreca Co-founderMaria Letizia Barreca is a medicinal chemist with expertise in molecular modeling, computational chemistry, and chemoinformatics; she is co-founder of Sibylla Biotech, which develops drug discovery technology for protein misfolding diseases.

Graziano LolliCo-founder

Investors · 8

3B Future Health Fund✓ confirmed by SibyllaMonaco · $12M

How we know: the company's own site · a partner's Signal profile · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us

CDP Venture Capital✓ confirmed by SibyllaRoma

How we know: CDP Venture Capital's portfolio page · the company's own site · press coverage · the VCSheet dataset · Not right? Tell us

Seroba Life Sciences✓ confirmed by SibyllaDublin · $540K – $7.6M

How we know: the company's own site · a partner's Signal profile · press coverage · Not right? Tell us

V-Bio Ventures✓ confirmed by SibyllaGhent · $270K – $2.2M

How we know: the company's own site · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us

Vertis SGR✓ confirmed by SibyllaNaples

How we know: the company's own site · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us

VI Partners✓ confirmed by SibyllaAltendorf · $2.2M – $4.5M

How we know: the company's own site · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us

Claris Ventureslisted by Claris VenturesTorino

How we know: Claris Ventures's portfolio page · a partner's Signal profile · press coverage · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Indaco Venture Partnerslisted by Indaco Venture PartnersMilan

How we know: Indaco Venture Partners's portfolio page · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us

In the news

Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform - Sibylla Biotechsibyllabiotech.it · Oct 2022

Sibylla Biotech Raises €23M in Series A Fundingfinsmes.com · Oct 2022

Investors - Sibylla Biotechsibyllabiotech.it · Jun 2021

Frequently asked questions

What does Sibylla do?: Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution. The company focuses on protein misfolding diseases, particularly prion diseases.
Who founded Sibylla?: Sibylla was founded by Emiliano Biasini, Pietro Faccioli, Giovanni Spagnolli, Maria Letizia Barreca, Graziano Lolli.
Who are Sibylla's investors?: Sibylla's investors include 3B Future Health Fund, CDP Venture Capital, Seroba Life Sciences, V-Bio Ventures, Vertis SGR, VI Partners, Claris Ventures, Indaco Venture Partners.
Where is Sibylla headquartered?: Sibylla is headquartered in Trento, IT.